Letermovir conversion after valganciclovir treatment in cytomegalovirus high‐risk abdominal solid organ transplant recipients may promote development of cytomegalovirus‐specific cell mediated immunity.
Saved in:
| Title: | Letermovir conversion after valganciclovir treatment in cytomegalovirus high‐risk abdominal solid organ transplant recipients may promote development of cytomegalovirus‐specific cell mediated immunity. |
|---|---|
| Authors: | Jorgenson, Margaret R1 (AUTHOR) mjorgenson@uwhealth.org, Kleiboeker, Hanna1 (AUTHOR), Garg, Neetika2 (AUTHOR), Parajuli, Sandesh2 (AUTHOR), Mandelbrot, Didier A2 (AUTHOR), Odorico, Jon S3 (AUTHOR), Saddler, Christopher M4 (AUTHOR), Smith, Jeannina A4 (AUTHOR) |
| Source: | Transplant Infectious Disease. Feb2022, Vol. 24 Issue 1, p1-9. 9p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
